April 17,2020 :The drug, a novel oral angio-immuno kinase inhibitor, is being developed for patients for whom surgery for such conditions is not feasible.
It’s dual action mechanism selectively inhibits the activity of tyrosine kinase associated with vascular endothelial growth factor receptor and fibroblast growth factor receptor, both inhibiting angiogenesis and colony-stimulating factor-1 receptor, which regulates tumor-associated macrophages, enhancing the body’s immune response to tumor cells.
Fast track desidnation could help speed up the production and approval of the drug, with the hope that it would meet unmet medical needs
https://fda.einnews.com/pr_news/514814945/chi-med-announces-surufatinib-granted-u-s-fda-fast-track-designations-for-the-treatment-of-both-pancreatic-and-non-pancreatic-neuroendocrine-tumors
